|Awarded On||February 21, 2018|
|Title||Prevalence of Rare Passenger Mutations in Biopsy Tissue as Cancer Stratification Markers|
|Award Mechanism||Individual Investigator|
|Principal Investigator/Program Director||David Zhang|
|Cancer Sites||All Sites|
Cancer is caused by acquired mutations in DNA, and different patients' cancer cells and tumors will possess different mutation rates. Only a small proportion of mutations are actually the drive" mutations that cause cancer, and thus far research efforts have focused on understanding and detecting these driver mutations. In contrast, non-pathogenic passenger mutations, considered the incidental by-products of cancer, have received relatively little study as potential markers for cancer diagnostic or prognostic tests. The PI hypothesizes that the prevalence of passenger mutations in a tissue biopsy sample may be correlated with the mutability of a patient's tumor. In other words, pati...